EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Higher 25(OH)D Levels at Admission Predict a Favorable Disease Evolution in Moderate-to-Severe COVID-19 Patients

Manuela Rizzi iD, Federica Vincenzi iD, Stelvio Tonello iD, Eleonora Rizzi, Giuseppe Francesco Casciaro, Erica Matino, Martina Costanzo, Erika Zecca iD, Alessandro Croce, Anita Pedrinelli, Veronica Vassia iD, Raffaella Landi und 9 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27083541 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Manuela Rizzi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze della Salute (DiSS), Università del Piemonte Orientale (UPO), 28100 Novara, Italy. Hauptthemen laut MEDLINE: COVID-19, Vitamin D. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministero della Salute, NextGeneration EU - MUR - M4C2 1.1, European Union-Next Generation EU, PNRR Mission 4 Component 2 Inv. 1.3.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research into effective predictive markers and therapeutic interventions for COVID-19 remains of considerable interest. Vitamin D may be relevant, especially in frail populations in whom deficiency is more prevalent. In this prospective observational cohort study, 139 patients with moderate-to-severe COVID-19 who were hospitalized during the third wave of the pandemic in Italy were enrolled. Plasma vitamin D concentrations (both 25-hydroxyvitamin D-25(OH)D and 1,25-dihydroxyvitamin D-1,25(OH)2D) together with parathyroid hormone levels were measured using a chemiluminescent assay validated for clinical use on automated laboratory platforms. Plasma vitamin D levels were below the sufficiency threshold. Notably, 25(OH)D concentrations were significantly lower in patients who experienced a negative outcome (11.10 [8.80–16.20] vs. 15.25 [9.90–24.80] ng/mL, p = 0.0450) and significantly higher in patients with rapid clinical recovery (15.25 [10.70–24.80] vs. 13.30 [7.47–19.60] ng/mL, p = 0.0446) compared with all other patients. Through multivariable logistic regression analysis, higher 25(OH)D levels at the time of hospitalization were confirmed as an independent predictor of favorable outcome. A plasma 25(OH)D concentration above 11.10 ng/mL predicted favorable disease resolution, with a positive likelihood ratio of 1.40 (IQR: 1.05–1.87). In conclusion, our findings support plasma vitamin D levels as an independent predictor of clinical outcomes in patients hospitalized with COVID-19 pneumonia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Vitamin DHumansFemaleSARS-CoV-2MaleAgedProspective StudiesParathyroid HormoneMiddle AgedBiomarkersItalyPandemicsHospitalizationSeverity of Illness Index

Stichwörter der Autor:innen

COVID-19biomarkerclinical outcomesvitamin D

Substanzen

Vitamin D25-hydroxyvitamin DParathyroid HormoneBiomarkers1,25-dihydroxyvitamin D

Autor:innen und Institutionen

  • Dipartimento di Scienze della Salute (DiSS), Università del Piemonte Orientale (UPO), 28100 Novara, Italy.
  • Dipartimento di Medicina Traslazionale (DiMeT), Università del Piemonte Orientale (UPO), 28100 Novara, Italy.
  • Internal Medicine and Rheumatology Department, Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, 28100 Novara, Italy.
  • Clinical Biochemistry Laboratory, Azienda Ospedaliero-Universitaria "Maggiore della Carità" di Novara, 28100 Novara, Italy.
  • IRCAD (Interdisciplinary Research Center of Autoimmune Diseases), Università del Piemonte Orientale (UPO), 28100 Novara, Italy.
  • CAAD (Center for Translational Research on Allergic and Autoimmune Diseases), Università del Piemonte Orientale (UPO), 28100 Novara, Italy.

ORCID-Profile: Manuela Rizzi, Federica Vincenzi, Stelvio Tonello, Erika Zecca, Veronica Vassia, Francesca Boccafoschi, Roberta Rolla, Luigi Mario Castello, Mario Pirisi, Donato Colangelo, Pier Paolo Sainaghi

Förderung

  • Italian Ministero della Salute
  • NextGeneration EU - MUR - M4C2 1.1
  • European Union-Next Generation EU, PNRR Mission 4 Component 2 Inv. 1.3
  • Ricerca Finalizzata
  • Next Generation EU-MUR–M4C2 1.1

Zitieren

APA

Rizzi, M., Vincenzi, F., Tonello, S., Rizzi, E., Casciaro, G. F., Matino, E., Costanzo, M., Zecca, E., Croce, A., Pedrinelli, A., Vassia, V., Landi, R., Zeqaj, I., Boccafoschi, F., Tillio, P. A., Rolla, R., Dianzani, U., Castello, L. M., Pirisi, M., …, & Sainaghi, P. P. (2026). Higher 25(OH)D Levels at Admission Predict a Favorable Disease Evolution in Moderate-to-Severe COVID-19 Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27083541

Vancouver

Rizzi M, Vincenzi F, Tonello S, Rizzi E, Casciaro GF, Matino E, et al. Higher 25(OH)D Levels at Admission Predict a Favorable Disease Evolution in Moderate-to-Severe COVID-19 Patients. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27083541

BibTeX
@article{Rizzi2026,
  author = {Rizzi, Manuela and Vincenzi, Federica and Tonello, Stelvio and Rizzi, Eleonora and Casciaro, Giuseppe Francesco and Matino, Erica and Costanzo, Martina and Zecca, Erika and Croce, Alessandro and Pedrinelli, Anita and Vassia, Veronica and Landi, Raffaella and Zeqaj, Iris and Boccafoschi, Francesca and Tillio, Paolo Amedeo and Rolla, Roberta and Dianzani, Umberto and Castello, Luigi Mario and Pirisi, Mario and Colangelo, Donato and Sainaghi, Pier Paolo},
  title = {Higher 25(OH)D Levels at Admission Predict a Favorable Disease Evolution in Moderate-to-Severe COVID-19 Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27083541}
}
Kostenlos starten →